跳转至内容
Merck
CN
  • Neuroprotective effects of bee venom acupuncture therapy against rotenone-induced oxidative stress and apoptosis.

Neuroprotective effects of bee venom acupuncture therapy against rotenone-induced oxidative stress and apoptosis.

Neurochemistry international (2014-12-08)
Wagdy K B Khalil, Naglaa Assaf, Shaimaa A ElShebiney, Neveen A Salem
摘要

Parkinson's disease (PD), the most common neurodegenerative movement disorder, is characterized by dopaminergic neurodegeneration, mitochondrial impairment, and oxidative stress. Exposure of animals to rotenone induces a range of responses characteristic of PD, including reactive oxygen species production and dopaminergic cell death. Although l-dopa is the drug of choice for improving core symptoms of PD, it is associated with involuntary movements. The current study was directed to evaluate the neuroprotective effect of bee venom acupuncture therapy (BVA) against rotenone-induced oxidative stress, neuroinflammation, and apoptosis in PD mouse model. Forty male Swiss mice were divided into four groups: (1) received saline solution orally and served as normal control, (2) received rotenone (1.5 mg/kg, s.c. every other day for 6 doses), (3) received rotenone concomitantly with l-dopa (25 mg/kg, daily, p.o. for 6 days), and finally (4) received rotenone concomitantly with BVA (0.02 ml once every 3 days for two weeks). Rotenone-treated mice showed impairment in locomotor behavior and a significant reduction in brain dopamine, serotonin, norepinephrine, GSH levels, and paraoxonase activity, whereas a significant increase was observed in brain malondialdehyde, tumor necrosis factor-α, interleukin-β levels besides DNA damage, and over-expression of caspase-3, Bax, and Bcl-2 genes. Significant improvement of the aforementioned parameters was demonstrated after BVA compared to l-dopa therapy. In conclusion, bee venom normalized all the neuroinflammatory and apoptotic markers and restored brain neurochemistry after rotenone injury. Therefore, BVA is a promising neuroprotective therapy for PD.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
氯仿, contains 100-200 ppm amylenes as stabilizer, ≥99.5%
Sigma-Aldrich
氯仿, contains ethanol as stabilizer, ACS reagent, ≥99.8%
Sigma-Aldrich
苯酚 溶液, Equilibrated with 10 mM Tris HCl, pH 8.0, 1 mM EDTA, BioReagent, Molecular Biology
Sigma-Aldrich
乙二胺四乙酸, ACS reagent, 99.4-100.6%, powder
Sigma-Aldrich
鱼藤酮, ≥95%
Sigma-Aldrich
氯仿, contains amylenes as stabilizer, ACS reagent, ≥99.8%
Sigma-Aldrich
乙二胺四乙酸, anhydrous, crystalline, BioReagent, suitable for cell culture
Sigma-Aldrich
苯酚, puriss., ≥99.5% (GC), meets analytical specification of Ph. Eur., BP, USP, crystalline (detached)
Sigma-Aldrich
乙二胺四乙酸 溶液, 0.02% in DPBS (0.5 mM), sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
乙二胺四乙酸 二钠盐 溶液, BioUltra, pH 8.0, ~0.5 M in H2O
Sigma-Aldrich
氯仿, ACS spectrophotometric grade, ≥99.8%, contains 0.5-1.0% ethanol as stabilizer
Sigma-Aldrich
氯仿, anhydrous, ≥99%, contains 0.5-1.0% ethanol as stabilizer
Sigma-Aldrich
乙二胺四乙酸, 99.995% trace metals basis
Sigma-Aldrich
乙二胺四乙酸, BioUltra, anhydrous, ≥99% (titration)
Sigma-Aldrich
氯仿, anhydrous, contains amylenes as stabilizer, ≥99%
Sigma-Aldrich
苯酚 溶液, Saturated with 0.01 M citrate buffer, pH 4.3 ± 0.2, BioReagent, Molecular Biology
Sigma-Aldrich
苯酚, ≥99%
Sigma-Aldrich
液状苯酚, ≥89.0%
Sigma-Aldrich
苯酚, puriss. p.a., ACS reagent, reag. Ph. Eur., 99.0-100.5%
Supelco
苯酚, Pharmaceutical Secondary Standard; Certified Reference Material
USP
苯酚, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
苯酚, Molecular Biology
Sigma-Aldrich
乙二胺四乙酸, purified grade, ≥98.5%, powder
Sigma-Aldrich
苯酚, BioXtra, ≥99.5% (GC)
Supelco
苯酚 溶液, certified reference material, 500 μg/mL in methanol
Sigma-Aldrich
苯酚, ACS reagent, ≥99.0%
Sigma-Aldrich
苯酚, unstabilized, ReagentPlus®, ≥99%
Supelco
氯仿, analytical standard
Sigma-Aldrich
苯酚, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.5-100.5% (GC)
Supelco
苯酚 溶液, 5000 μg/mL in methanol, certified reference material